SCHEMBL832196

SCHEMBL832196

CCc1ccc2c(c1)c(-c1ccc[nH]c1=O)c(C(=O)NS(=O)(=O)C1(C)CC1)n2Cc1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.43
PARG Q86W56 3/20 0.40
KMT2A Q03164 4/20 0.39
MEN1 O00255 1/20 0.37
MAPT P10636 2/20 0.35
TP53 P04637 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EDNRB P24530 1/20 0.34
PTGDR2 Q9Y5Y4 1/20 0.34
ECE1 P42892 1/20 0.33
PTGER4 P35408 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
AGTR1 P30556 1/20 0.32
AGTR2 P50052 1/20 0.32
PTGER3 P43115 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830600 0.91 CYP2C8 (0.39) CYP2C8PARGKMT2AMEN1MAPT
SCHEMBL831179 0.91 CYP2C8 (0.46) CYP2C8PARGKMT2AMEN1MAPT
SCHEMBL862351 0.89 CYP2C8 (0.43) CYP2C8PARGKMT2AMEN1MAPT
SCHEMBL831530 0.89 CYP2C8 (0.43) CYP2C8PARGKMT2AMEN1MAPT
SCHEMBL832478 0.89 CYP2C8 (0.43) CYP2C8PARGKMT2AMEN1ECE1
SCHEMBL831751 0.87 CYP2C8 (0.41) CYP2C8PARGKMT2AMEN1MAPT
SCHEMBL830785 0.87 CYP2C8 (0.42) CYP2C8PARGKMT2AMEN1MAPT
SCHEMBL831986 0.87 CYP2C8 (0.38) CYP2C8PARGKMT2AMEN1MAPT
SCHEMBL831963 0.86 CYP2C8 (0.40) CYP2C8PARGKMT2AMEN1MAPT
SCHEMBL831787 0.86 CYP2C8 (0.40) CYP2C8PARGKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885PARG 3471/4885KMT2A 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.